Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 6/2020

26.02.2020 | Original Article

Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma

verfasst von: Lata Singh, Mithalesh Kumar Singh, Moshahid Alam Rizvi, Sameer Bakhshi, Rachna Meel, Neiwete Lomi, Seema Sen, Seema Kashyap

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this study is to identify the pathological findings and expression of immune checkpoint marker (PD-1, PD-L1, and CTLA-4) in the tumor microenvironment of both primary and chemoreduced retinoblastoma and correlate them with clinicopathological parameters and patient outcome.

Methods

Total of 262 prospective cases was included prospectively in which 144 cases underwent primary enucleation and 118 cases received chemotherapy/radiotherapy before enucleation (chemoreduced retinoblastoma). Immunohistochemistry, qRT-PCR and western blotting were performed to evaluate the expression pattern of immune checkpoint markers in primary and chemoreduced retinoblastoma.

Results

Tumor microenvironment were different for both primary and chemoreduced retinoblastoma. Expression of PD-1 was found in 29/144 (20.13%) and 48/118 (40.67%) in primary and chemoreduced retinoblastoma, respectively, whereas PD-L1 was expressed in 46/144 (31.94%) and 22/118 (18.64%) in cases of primary and chemoreduced retinoblastoma, respectively. Expression pattern of CTLA-4 protein was similar in both groups of retinoblastoma. On multivariate analysis, massive choroidal invasion, bilaterality and PD-L1 expression (p = 0.034) were found to be statistically significant factors in primary retinoblastoma, whereas PD-1 expression (p = 0.015) and foamy macrophages were significant factors in chemoreduced retinoblastoma. Overall survival was reduced in cases of PD-L1 (80.76%) expressed primary retinoblastoma, and PD-1 (63.28%) expressed chemoreduced retinoblastoma.

Conclusions

This is the first of its kind study predicting a relevant role of the immune checkpoint markers in both groups of primary and chemoreduced retinoblastoma with prognostic significance. Differential expression of these markers in both group of retinoblastoma is a novel finding and might be an interesting and beneficial target for chemoresistant tumors.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Chawla B, Singh R (2017) Recent advances and challenges in the management of retinoblastoma. Indian J Ophthalmol 65(2):133–139PubMedPubMedCentral Chawla B, Singh R (2017) Recent advances and challenges in the management of retinoblastoma. Indian J Ophthalmol 65(2):133–139PubMedPubMedCentral
3.
Zurück zum Zitat Ghassemi F, Khodabande A (2015) Risk definition and management strategies in retinoblastoma: current perspectives. Clin ophthalmol 9:985–994PubMedPubMedCentral Ghassemi F, Khodabande A (2015) Risk definition and management strategies in retinoblastoma: current perspectives. Clin ophthalmol 9:985–994PubMedPubMedCentral
4.
Zurück zum Zitat Yanık Ö, Gündüz K, Yavuz K et al (2015) Chemotherapy in retinoblastoma: current approaches. Turk J Ophthalmol 45(6):259–267PubMedPubMedCentral Yanık Ö, Gündüz K, Yavuz K et al (2015) Chemotherapy in retinoblastoma: current approaches. Turk J Ophthalmol 45(6):259–267PubMedPubMedCentral
5.
Zurück zum Zitat Gombos DS, Hungerford J, Abramson DH et al (2007) Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114(7):1378–1383PubMed Gombos DS, Hungerford J, Abramson DH et al (2007) Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114(7):1378–1383PubMed
6.
Zurück zum Zitat Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat med 19(11):1423–1437PubMedPubMedCentral Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat med 19(11):1423–1437PubMedPubMedCentral
7.
Zurück zum Zitat Chen F, Zhuang X, Lin L et al (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13(1):45PubMedPubMedCentral Chen F, Zhuang X, Lin L et al (2015) New horizons in tumor microenvironment biology: challenges and opportunities. BMC Med 13(1):45PubMedPubMedCentral
8.
9.
Zurück zum Zitat Sachdeva UM, O’Brien JM (2012) Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma. J Clin Invest 122(2):425–434PubMedPubMedCentral Sachdeva UM, O’Brien JM (2012) Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma. J Clin Invest 122(2):425–434PubMedPubMedCentral
10.
Zurück zum Zitat Fang H, Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73(16):4695–4777 Fang H, Declerck YA (2013) Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res 73(16):4695–4777
11.
Zurück zum Zitat Shih K, Arkenau HT, Infante JR (2014) Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74(17):1993–2013PubMedPubMedCentral Shih K, Arkenau HT, Infante JR (2014) Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 74(17):1993–2013PubMedPubMedCentral
12.
Zurück zum Zitat Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 Therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86PubMedPubMedCentral Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and Anti-CTLA-4 Therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86PubMedPubMedCentral
13.
Zurück zum Zitat Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMed Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMed
14.
Zurück zum Zitat Henick BS, Herbst RS, Goldberg SB (2014) The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 18(12):1407–1420PubMed Henick BS, Herbst RS, Goldberg SB (2014) The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opin Ther Targets 18(12):1407–1420PubMed
15.
Zurück zum Zitat Yang W, Li H, Chen PW et al (2009) PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 50(1):273–280PubMed Yang W, Li H, Chen PW et al (2009) PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 50(1):273–280PubMed
16.
Zurück zum Zitat Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561PubMedPubMedCentral Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561PubMedPubMedCentral
17.
Zurück zum Zitat Udall M, Rizzo M, Kenny J et al (2018) PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol 13(1):12PubMedPubMedCentral Udall M, Rizzo M, Kenny J et al (2018) PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol 13(1):12PubMedPubMedCentral
18.
Zurück zum Zitat Juneja VR, McGuire KA, Manguso RT et al (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214(4):895–904PubMedPubMedCentral Juneja VR, McGuire KA, Manguso RT et al (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214(4):895–904PubMedPubMedCentral
19.
Zurück zum Zitat Wang Q, Liu F, Liu L (2017) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine 96(18):e6369PubMedPubMedCentral Wang Q, Liu F, Liu L (2017) Prognostic significance of PD-L1 in solid tumor: an updated meta-analysis. Medicine 96(18):e6369PubMedPubMedCentral
20.
Zurück zum Zitat Pianko MJ, Liu Y, Bagchi S et al (2017) Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig 4:32PubMedPubMedCentral Pianko MJ, Liu Y, Bagchi S et al (2017) Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig 4:32PubMedPubMedCentral
21.
Zurück zum Zitat Mallipatna A, Gallie BL, Chévez-Barrios P (2017) Retinoblastoma. In: Amin MB, Edge SB, Greene FL (eds) AJCC Cancer Staging Manual, 8th edn. Springer, New York, NY, pp 819–831 Mallipatna A, Gallie BL, Chévez-Barrios P (2017) Retinoblastoma. In: Amin MB, Edge SB, Greene FL (eds) AJCC Cancer Staging Manual, 8th edn. Springer, New York, NY, pp 819–831
22.
Zurück zum Zitat Di Nicolantonio F, Neale M, Onadim Z et al (2003) The chemosensitivity profile of retinoblastoma. In: Chemosensitivity testing in oncology. Springer, Berlin, pp 73–80 Di Nicolantonio F, Neale M, Onadim Z et al (2003) The chemosensitivity profile of retinoblastoma. In: Chemosensitivity testing in oncology. Springer, Berlin, pp 73–80
23.
Zurück zum Zitat Radhakrishnan V, Kashyap S, Pushker N et al (2012) Outcome, pathologic findings, and compliance in orbital retinoblastoma (international retinoblastoma staging system stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 119(7):1470–1477PubMed Radhakrishnan V, Kashyap S, Pushker N et al (2012) Outcome, pathologic findings, and compliance in orbital retinoblastoma (international retinoblastoma staging system stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 119(7):1470–1477PubMed
24.
Zurück zum Zitat Usui Y, Okunuki Y, Hattori T et al (2006) Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. Invest Ophthalmol Vis Sci 47(10):4607–4613PubMed Usui Y, Okunuki Y, Hattori T et al (2006) Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. Invest Ophthalmol Vis Sci 47(10):4607–4613PubMed
25.
Zurück zum Zitat Li H, Li X, Liu S et al (2017) Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 66(6):1920–1933PubMed Li H, Li X, Liu S et al (2017) Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. Hepatology 66(6):1920–1933PubMed
26.
Zurück zum Zitat Kleffel S, Posch C, Barthel SR et al (2015) Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162(6):1242–1256PubMedPubMedCentral Kleffel S, Posch C, Barthel SR et al (2015) Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 162(6):1242–1256PubMedPubMedCentral
27.
Zurück zum Zitat Du S, McCall N, Park K et al (2018) Blockade of tumor-expressed PD-1 promotes lung cancer growth. Oncoimmunology 7(4):e1408747PubMedPubMedCentral Du S, McCall N, Park K et al (2018) Blockade of tumor-expressed PD-1 promotes lung cancer growth. Oncoimmunology 7(4):e1408747PubMedPubMedCentral
28.
Zurück zum Zitat Yao H, Wang H, Li C et al (2018) Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol 9:1774PubMedPubMedCentral Yao H, Wang H, Li C et al (2018) Cancer cell-intrinsic PD-1 and implications in combinatorial immunotherapy. Front Immunol 9:1774PubMedPubMedCentral
29.
Zurück zum Zitat Raguraman R, Parameswaran S, Kanwar JR et al (2019) Evidence of tumour microenvironment and stromal cellular components in retinoblastoma. Ocul Oncol Pathol 5(2):85–93PubMed Raguraman R, Parameswaran S, Kanwar JR et al (2019) Evidence of tumour microenvironment and stromal cellular components in retinoblastoma. Ocul Oncol Pathol 5(2):85–93PubMed
30.
Zurück zum Zitat Lotfi R, Kaltenmeier C, Lotze MT et al (2016) Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfus Med Hemother 43(2):120–132PubMedPubMedCentral Lotfi R, Kaltenmeier C, Lotze MT et al (2016) Until death do us part: necrosis and oxidation promote the tumor microenvironment. Transfus Med Hemother 43(2):120–132PubMedPubMedCentral
31.
Zurück zum Zitat Chong EM, Coffee RE, Chintagumpala M et al (2006) Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med 130(11):1669–1672PubMed Chong EM, Coffee RE, Chintagumpala M et al (2006) Extensively necrotic retinoblastoma is associated with high-risk prognostic factors. Arch Pathol Lab Med 130(11):1669–1672PubMed
32.
Zurück zum Zitat Lotfi R, Schrezenmeier H, Lotze MT (2009) Immunotherapy for cancer: promoting innate immunity. Front Biosci 14:818–832 Lotfi R, Schrezenmeier H, Lotze MT (2009) Immunotherapy for cancer: promoting innate immunity. Front Biosci 14:818–832
33.
Zurück zum Zitat Thompson RH, Kuntz SM, Leibovich BC et al (2006) Tumor B7–H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385PubMed Thompson RH, Kuntz SM, Leibovich BC et al (2006) Tumor B7–H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385PubMed
34.
Zurück zum Zitat Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat immunol 14(10):1014–1022PubMedPubMedCentral Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat immunol 14(10):1014–1022PubMedPubMedCentral
35.
Zurück zum Zitat Richards DM, Hettinger J, Feuerer M (2013) Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 6(2):179–191PubMed Richards DM, Hettinger J, Feuerer M (2013) Monocytes and macrophages in cancer: development and functions. Cancer Microenviron 6(2):179–191PubMed
36.
Zurück zum Zitat de Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277–286PubMed de Palma M, Lewis CE (2013) Macrophage regulation of tumor responses to anticancer therapies. Cancer Cell 23(3):277–286PubMed
37.
Zurück zum Zitat Demirci H, Eagle RC, Shields CL et al (2003) Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 121(8):1125–1131PubMed Demirci H, Eagle RC, Shields CL et al (2003) Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol 121(8):1125–1131PubMed
38.
Zurück zum Zitat Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84(3):623–630PubMedPubMedCentral Pollard JW (2008) Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84(3):623–630PubMedPubMedCentral
39.
Zurück zum Zitat Long M, Beckwith K, Do P et al (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 127(8):3052–3064PubMedPubMedCentral Long M, Beckwith K, Do P et al (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 127(8):3052–3064PubMedPubMedCentral
40.
Zurück zum Zitat Mesnage SJ, Auguste A, Genestie C et al (2016) Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann of Oncol 28(3):651–657 Mesnage SJ, Auguste A, Genestie C et al (2016) Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann of Oncol 28(3):651–657
41.
Zurück zum Zitat Katsuya Y, Horinouchi H, Asao T et al (2016) Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer 99:4–10PubMed Katsuya Y, Horinouchi H, Asao T et al (2016) Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: impact on treatment efficacy and alteration in expression after chemotherapy. Lung Cancer 99:4–10PubMed
42.
Zurück zum Zitat Kim HS, Kim JY, Lee YJ et al (2018) Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecol oncol 151(3):414–421PubMed Kim HS, Kim JY, Lee YJ et al (2018) Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecol oncol 151(3):414–421PubMed
43.
Zurück zum Zitat Sheng J, Fang W, Yu J et al (2016) Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 6:20090PubMedPubMedCentral Sheng J, Fang W, Yu J et al (2016) Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 6:20090PubMedPubMedCentral
44.
Zurück zum Zitat Meng Y, Liang H, Hu J et al (2018) PD-L1 Expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 9(16):2938–2945PubMedPubMedCentral Meng Y, Liang H, Hu J et al (2018) PD-L1 Expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer. J Cancer 9(16):2938–2945PubMedPubMedCentral
45.
Zurück zum Zitat Wimberly H, Brown JR, Schalper K et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332PubMed Wimberly H, Brown JR, Schalper K et al (2015) PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 3(4):326–332PubMed
46.
Zurück zum Zitat Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):39PubMedPubMedCentral Chae YK, Arya A, Iams W et al (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):39PubMedPubMedCentral
47.
Zurück zum Zitat Chen X, Kunda PE, Lin J et al (2018) SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma. J Cancer Res Clin Oncol 144(4):675–684PubMedPubMedCentral Chen X, Kunda PE, Lin J et al (2018) SYK-targeted dendritic cell-mediated cytotoxic T lymphocytes enhance the effect of immunotherapy on retinoblastoma. J Cancer Res Clin Oncol 144(4):675–684PubMedPubMedCentral
48.
Zurück zum Zitat Singh L, Singh MK, Rizvi MA, Pushker N, Sen S, Kashyap S (2019) Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma. Ann Oncol 30(11):447003 Singh L, Singh MK, Rizvi MA, Pushker N, Sen S, Kashyap S (2019) Differential expression patterns of immune checkpoint markers in tumour-stromal microenvironment of primary and chemoreduced retinoblastoma. Ann Oncol 30(11):447003
Metadaten
Titel
Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma
verfasst von
Lata Singh
Mithalesh Kumar Singh
Moshahid Alam Rizvi
Sameer Bakhshi
Rachna Meel
Neiwete Lomi
Seema Sen
Seema Kashyap
Publikationsdatum
26.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 6/2020
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02529-4

Weitere Artikel der Ausgabe 6/2020

Cancer Immunology, Immunotherapy 6/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.